Alpha-1 Antitrypsin Deficiency (AATD)


Hagit Baris-Feldman

Israel Emerges as Global Powerhouse in Rare Disease Research

TEL AVIV, Israel — On the 6th floor of Schneider Children’s Hospital in the Tel Aviv suburb of Petah Tikva, 30 children with Alagille syndrome and 2 with lysosomal acid lipase deficiency (LAL-D) receive specialized treatment from a trio of pediatric hepatologists. Across town, at Sheba Medical Center’s Edmond and Lily Safra Children’s Hospital, pediatric…
Stem cell research

Researchers Exploring Multiple Mechanisms of Action for Treating AATD

Faron Schonfeld, a successful investment portfolio manager from Philadelphia, Pennsylvania, had for years suffered chronic coughing and sinus infections that only seemed to get worse. He was finally referred to a pulmonologist at National Jewish Health in Denver, Colorado.  That’s where he got the diagnosis: Schonfeld had alpha-1 antitrypsin deficiency (AATD, or simply alpha-1) —…

Emerging Therapies, COVID-19 Highlight Alpha-1 Foundation’s Upcoming ‘Virtual Education Day’

Alpha-1 antitrypsin deficiency (AATD) is among the most common life-threatening genetic diseases to affect adult Caucasians worldwide. Yet for years, there’s only been one way to treat it: augmentation therapy. All 4 augmentation therapy products approved by the US Food and Drug Administration (FDA) involve taking alpha-1 antitrypsin protein (AAT) from the plasma of healthy…

Patient Perspectives

Healthy Living With AATD Requires Discipline, Knowledge

There are several things I would have done differently after my alpha1-antitrypsin deficiency (AATD) diagnosis. I did have a great doctor, but there were certain things I wish I had realized were so important. I once heard someone else with AATD say: “Nothing about respiratory illness is straightforward.” While this is true, so much can…

Alpha-1 Clinical Insights

Rare Care Podcast

Mark Brantly, MD, scientific director of the Alpha-1 Foundation, is the vice-chair of research in the Department of Medicine at the University of Florida in Gainesville, and has spent most of his career researching a cure for alpha-1 antitrypsin deficiency (AATD).

Alpha-1 Meeting Coverage